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Abstract
Background: Type 2 diabetes is treated in a stepwise manner, progressing from diet and physical activity to oral
antidiabetic agents and insulin. The oral agent pioglitazone is licensed for use with insulin when metformin is
contraindicated or not tolerated. This systematic review and meta-analysis investigates the extent to which adding
pioglitazone to insulin-containing regimens produces benefits in terms of patient-relevant outcomes.
Methodology/Principal Findings: Medline, Embase, and the Cochrane Library were searched for randomised controlled
trials comparing pioglitazone in combination with any insulin-containing regimen in comparison with the same insulin
regimen alone in patients with type 2 diabetes. Outcomes investigated included HbA1c, hypoglycaemia, weight, and
adverse events. Studies were selected, assessed and summarised according to standard systematic review methodology and
in a meta-analysis. We included eight trials that examined the benefits of adding pioglitazone to an insulin regimen and
studied a total of 3092 patients with type 2 diabetes. All studies included patients with previously inadequate glucose
control. Trial duration was between 12 weeks and 34.5 months. The trials used pioglitazone doses of up to 45 mg/day. In
our meta-analysis, the mean reduction in HbA1c was 0.58% (95% CI: 20.70, 20.46, p,0.00001). Hypoglycaemic episodes
were slightly more frequent in the pioglitazone arms (relative risk 1.27; 95% CI: 0.99, 1.63, p=0.06). Where reported, HDL-
cholesterol tended to be increased with pioglitazone. Patients on pioglitazone tended to gain more weight than those who
were not, with an average difference of almost 3 kg. Peripheral oedema was more frequent in the pioglitazone groups.
None of the studies reported on fractures in women, and data on cardiovascular events were inconclusive, with most
studies being too short or too small to assess these long-term outcomes.
Conclusions/Significance: When added to insulin regimens, pioglitazone confers a small advantage in terms of HbA1c in
type 2 diabetes patients with previous inadequate glucose control, but at the cost of increased hypoglycaemia and weight
gain. Other considerations include the risk of heart failure, fractures in women, a reduced insulin dose, and the net financial
cost.
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Introduction
Type 2 diabetes is usually seen in people who are overweight or
obese, particularly if inactive. They usually have insulin resistance,
and therefore require higher levels of insulin in order to keep blood
glucose within the normal range. The pancreatic beta cell is
initially able to compensate for insulin resistance by increasing
production, thereby maintaining normal blood glucose levels.
However, in most patients, pancreatic beta cell function
progressively declines, leading to hyperglycaemia and clinical
diabetes[1]. In the United Kingdom Prospective Diabetes Study
(UKPDS), beta-cell function was found to be impaired at
diagnosis, especially in patients who were not overweight[2].
The difficulty in maintaining metabolic control over time may
be related to several behavioural factors (for example difficulties
with healthy eating, exercise, medication regimens) but also
reflects a progressive decline in beta-cell function[3,4].
Type 2 diabetes has traditionally been treated in a stepwise
manner, starting with lifestyle modifications and encouragement of
physical activity and when necessary, pharmacotherapy with oral
agents (NICE guideline)[5]. If control remains inadequate, insulin
may be used, with or without combination with one or more oral
agents. There is no clear consensus on the definition of
‘‘inadequate control’’, but a consensus statement (2009) of a
working group drawn from the American Diabetes Association
and the European Association for the Study of Diabetes suggested
that ‘‘an HbA1c over 7% should serve as a call to action to initiate
or change therapy’’[6].
Several classes of oral agents are available. These include the
insulin secretagogues which stimulate the pancreas to release more
insulin, by binding to a sulphonylurea receptor, the main group
being the sulphonylureas; a second class are the insulin sensitizers,
including the biguanide metformin and the thiazolidinediones
rosiglitazone and pioglitazone; thirdly there are drugs that delay
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such as acarbose; fourthly there are the DPP-IV inhibitors (also
known as the gliptins), which extend the life of endogenous
glucagon-like peptide. These include sitagliptin and vildagliptin
(with more in development).
The glitazones
The thiazolidinediones – or glitazones for short – decrease
insulin resistance in muscle and adipose tissue by activating the
peroxisome proliferator-activated receptor-gamma (PPAR- gam-
ma) which increases production of proteins involved in glucose
uptake. They also decrease hepatic glucose production by
improving hepatic insulin sensitivity.
According to the Prescribing Support Unit (PSU), in collabo-
ration with the York and Humber Public Health Observatory
(YHPHO)[7], the glitazones are the third most used diabetes drugs
in England (about 2.4 million prescriptions a year), after
metformin (about 10 million prescriptions a year), and the
sulphonylureas (around 5 million prescriptions a year). In terms
of cost per annum, the glitazones are by far the most costly, being
recently introduced drugs with no generic forms.
In addition to being used alone or in combination with other
oral agents, pioglitazone is also licensed (EMEA 2008)[8] for use in
combination with insulin in type 2 diabetes patients with
insufficient glycaemic control on insulin, and for whom metformin
is inappropriate because of contraindications or intolerance. In
this review, we concentrate on this indication.
A Cochrane review of pioglitazone therapy in general by
Richter et al. (2006)[9] included 22 trials which randomised a total
of 6200 people to pioglitazone treatment. Most studies were of
short duration. Published studies of at least 24 weeks pioglitazone
treatment in people with type 2 diabetes mellitus did not provide
convincing evidence of benefit in patient oriented outcomes like
mortality, morbidity, adverse effects, costs and health-related
quality of life. Metabolic control measured by HbA1c did not
demonstrate clinically relevant differences to other oral glucose
lowering drugs. The occurrence of oedema was significantly
raised.
The only exception to the short-term trials found in the
Cochrane review was the PROactive study[10]. This placebo
controlled randomised trial of 5238 patients set out to determine
the effect of pioglitazone on macrovascular morbidity and
mortality in patients with type 2 diabetes who had evidence of
macrovascular disease. Patients continued their other diabetes
medications, mainly metformin, sulphonylureas, insulin, or
combinations thereof. The primary end-point was a composite
of death and non-fatal cardiovascular outcomes. The average time
of observation was 34.5 months. The pioglitazone group had a
lower risk but this did not reach statistical significance (HR 0.90,
95% CI 0.80 to 1.02; p=0.095) despite the large numbers of
recruits and events (at least one end-point event in 514 of the
pioglitazone group and 572 of the placebo group). A secondary
endpoint measure of death, non-fatal MI and stroke did reach
statistical significance: HR 0.84, 0.72–0.98; p=0.027.
However, oedema and heart failure were commoner in the
pioglitazone group, with 11% reported as having heart failure
compared to 8% in the placebo group; the proportions needing
hospital admission were 6% and 4%. The death rates from heart
failure showed no difference. Heart failure was not defined
centrally, but was ‘‘as judged by the investigator’’. Another
outcome was ‘‘oedema in the absence of heart failure’’. Heart
failure can be difficult to diagnose, and the absence of any
difference in mortality from heart disease, might suggest that it
could have been over-diagnosed. However, an independent group
of cardiologists reviewed all the cases of serious heart failure and
concluded that it did occur more frequently in the pioglitazone
group (5.5% versus 4.2% for placebo)[11].
Another finding from PROactive was that progression to
needing insulin was halved in the pioglitazone group. At the start
of the study, about one-third of the patients were on insulin. Their
mean age was 62, mean BMI 31, and duration of diabetes 8 years;
75% had a history of hypertension and mean HbA1c was around
7.8%. The protocol asked investigators to aim for an HbA1c of
,6.5%. By the end of follow-up, 11% of the pioglitazone group
and 21% of the placebo group were on insulin treatment. The
switch to insulin started early in the trial, presumably due to
investigators trying to achieve the HbA1c target.
As concerns evidence on a combination of insulin and a
glitazone, Strowig and Raskin (2005)[12] carried out a review of
combination therapy with insulin and either metformin or a
glitazone, or both. Details of methods are not given and the review
was probably not systematic. The authors concluded that it was
worthwhile continuing an insulin sensitiser in type 2 diabetes
patients switched to insulin. Because metformin and glitazones
have different balances of sites of preferential action (acting on
glucose production and glucose disposal), they also made the case
that triple therapy may be considered. Bailey (2005)[13] also
supported combination therapy with metformin and a glitazone
for reducing insulin resistance in type 2 diabetes.
Objectives
This review investigates the extent to which adding pioglitazone
to insulin-containing regimens affects glycaemic control, hypogly-
caemia, weight change, lipids, and adverse events.
Methods
Study characteristics
We considered randomised controlled trials of pioglitazone in
combination with any insulin regimen in patients of any age and
gender with type 2 diabetes. Minimum trial duration was 12
weeks. Pioglitazone in combination with any insulin regimen
(long-acting, twice daily mixture, both with or without additional
oral medication (generally metformin and/or sulphonylurea)) was
compared to the same insulin regimen (with or without the same
additional oral regimen) given on its own. As outcome measures,
we considered HbA1c, frequency of hypoglycaemia (especially if
severe), glycaemic excursions (including post-prandial hypergly-
caemia), total daily dose of insulin, weight change, changes in
cardiovascular risk factors, and other adverse events.
We used a group of outcomes because the decision to use
pioglitazone was expected to depend on trade-offs amongst them,
such as better control versus weight gain. We would have
considered diabetic secondary complication rates (retinopathy,
nephropathy, myocardial infarction, angina, heart failure, stroke,
amputation, death), and health-related quality of life, but it rapidly
became clear that data would not be available.
Ethics
As this was a systematic review of published literature, ethics
approval was not required.
Searching
Medline, the Cochrane Library, and Embase were searched for
studies published between 1996 and 2008. The following Medline
search strategy (Ovid) was adapted for use with the other
databases:
Pioglitazone/Insulin in DM 2
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2. pioglitazone.tw.
3. 1 or 2
4. randomized controlled trial.pt.
5. meta-analysis.pt.
6. (random$ or meta-analysis or systematic review).tw.
7. 4 or 5 or 6
8. 3 and 7
In addition, reference lists of retrieved studies were checked.
Searches were also done to identify emerging evidence, from
conference abstracts and trial registers.
Selection
Studies were selected independently by two authors (PR and
NW) based on the inclusion criteria listed above. Any discrepan-
cies were resolved by discussion.
Validity assessment
Randomised controlled trials were assessed on the following
criteria based on the NICE guidelines manual[14]: Method of
randomisation, allocation concealment, blinding of participants
and outcome assessors, intention-to-treat analysis, proportion of
participants excluded/lost to follow-up, power calculation, com-
parability of groups at baseline. Subgroup analysis based on
quality was carried out for five or six or more quality criteria met
versus fewer than five or six quality criteria met (i.e. two analyses
with different cut-offs were done).
Data abstraction
Data extraction was carried out by one researcher and checked
by another. Any disagreements were resolved through discussion,
involving a third person if necessary.
Data synthesis
The clinical effectiveness, relative to the key comparators, was
assessed, in terms of difference in effect size.
Data were summarised in a meta-analysis and using tables and
text. For dichotomous outcomes, risk ratios were calculated and a
Mantel-Haenszel random effects model was used. For continuous
outcomes, weighted mean differences were calculated and an
inverse variance random effects model was used. Where not
directly available, standard deviations required in the meta-
analysis were converted from standard errors; if a measure of
variability was not given and standard deviations were available
for at least 50% of included studies, the mean of the standard
deviations of the remaining studies was used. Heterogeneity was
assessed using the chi-squared test.
Results
Trial flow
Eleven papers were identified as potentially relevant rando-
mised controlled trials. Of these, eight fulfilled the inclusion
criteria and compared pioglitazone plus insulin with insulin [15–
22]. The remaining trials were excluded because they did not
examine the comparison of interest and one was the uncontrolled
extension of a trial that seemed relevant but could not be identified
(see Figure 1).
Study characteristics
Characteristics of the included trials are shown in Table 1.
Design. Seven trials were randomised double-blind placebo-
controlled trials[15–18,20–22], while one trial was a randomised
open label trial[19]. The studies had different emphases: Asnani
2006 and Fernandez 2008 focussed on vascular reactivity;
Berhanu 2007 focussed on reduction of insulin dosage; Mattoo
2005 focussed on glycaemic control, lipids and cardiovascular risk
factors; Raz 2005 and Rosenstock 2002 focussed on glycaemic
control; Scheen 2006 focussed on secondary prevention of
macrovascular events; and Shah 2007 focussed on body fat
distribution. Trial duration ranged between 12 weeks and 34.5
months. Five trials were from the USA[15–17,20,22], one
included centres from a range of European countries[21], and
two included centres worldwide[18,19].
Participants. The trials included between 20 and 1760
participants, with between 10 and 896 participants in each
comparison group. The total number of patients assessed was
3092. All studies included participants with previously inadequate
glucose control (with different definitions, not reported for Shah
2007). Inclusion criteria with respect to previous treatment varied
substantially. Only five trials[15,17,18,20,22] required previous
insulin treatment. Three trials[15,18,20] required previous insulin
therapy with or without oral antidiabetic agents (where reported,
previous insulin monotherapy ranged between 48 and 88%). The
trial by Fernandez 2008 required previous insulin combination
therapy[17], and the trials by Shah 2007 included only insulin-
treated obese patients[22]. Of the remaining trials, the trial by
Berhanu 2007[16] required previous combination therapy with or
without insulin, and in this trial between 90 and 93% of patients
had been on sulphonylurea plus metformin therapy without
insulin. The study by Raz 2005[19] required previous therapy
with sulphonylurea (alone or as oral combination therapy) and
over 80% of patients in that trial had been on sulphonylurea plus
metformin previously. The study by Scheen 2006[21] included
patients previously on diet alone, oral agents, or insulin plus an
oral agent, and in that trial, over half the patients (53%) had been
on sulphonylurea plus insulin, and the second largest group had
been on sulphonylurea monotherapy (24%). Where reported,
mean age of participants was between 46 to 59 years, the
comparison groups included between 35 and 60% of women,
mean BMI was between 29 and 37 kg/m
2, and diabetes duration
was between 6 and 14 years. The trial by Berhanu 2007[16]
included between 50 and 59% of Hispanic participants, and the
study by Fernandez 2008 included only Mexican-American
participants[17].
Interventions. The trials used pioglitazone doses up to
45 mg/day. Four trials used titration schemes for pioglitazone
(up to 45 mg/day, usually starting at 15 mg/day)[16,17,21,22].
Three trials used fixed doses of 30 mg/day[15,18,19]. Rosenstock
2002 compared two pioglitazone doses, 15 and 30 mg/day[20].
As concerns the insulin therapy, Asnani 2006, Rosenstock 2002
and Scheen 2006 only specified that insulin therapy was continued
as before. Rosenstock 2002 used a single blind insulin monother-
apy lead-in period. Berhanu 2007 used a four week titration period
for insulin (Humalog, Humulin 70/30 or Humulin N) and defined
a target fasting plasma glucose of less than 140 mg/dL while
avoiding hypoglycaemia. In the study by Fernandez 2008, patients
could choose between multiple daily injections (basal-bolus
therapy using combination of insulin glargine at bedtime plus
premeal insulin aspart) or continuous subcutaneous infusions
(basal infusion and premeal boluses of insulin aspart) and defined
targets for blood glucose values (fasting and pre-meal capillary
blood glucose 80–120 mg/dL, 2-h post-meal glucose ,160 mg/
dL, bedtime glucose ,140 mg/dL). Mattoo 2005 used a three
month insulin intensification period before randomisation; the
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hypoglycaemia and adjusted thereafter based on self-monitored
blood glucose levels. Raz 2005 used biphasic insulin aspart 30/70.
In the study by Scheen 2006, concomitant therapy with metformin
was used by 47 to 52%, sulphonylurea alone by 16%, and
metformin plus sulphonylurea by 10 to 11%. Shah 2007 did not
give details of the insulin therapy.
Various studies specified co-interventions. Asnani 2006 allowed
stable lipid lowering therapy with statins and anti-hypertensive
therapy (including ACE inhibitors in all patients). In the study by
Berhanu 2007 statins and metformin where continued as before.
Fernandez 2008 changed all patients previously on ACE inhibitors
or angiotensin II receptor blockers for blood pressure control to
alpha-methyl dopa. Fernandez 2005 and Rosenstock 2002 allowed
lipid lowering therapy as used before the study.
Outcomes. The trials used a variety of primary endpoints.
HbA1c was the primary endpoint in the studies by Mattoo 2005,
Raz 2005 and Rosenstock 2002. The primary endpoint in the
study by Asnani 2006 was flow-mediated dilatation, in the study by
Berhanu 2007 it was change in insulin dosage, Fernandez 2008
used vascular analyses as primary endpoint, the primary endpoint
in the study by Scheen 2006 was a composite macrovascular
endpoint, and in the study by Shah 2007 it was body fat
distribution. All studies reported on end of study HbA1c values, six
studies reported on hypoglycaemia[16–21], one study reported on
glycaemic excursions[19], six studies reported on total daily
dose[16–21], six studies reported on weight change[16–20,22],
five studies reported on adverse events[16,18–21], six studies
reported on lipid parameters[15–20], while none of the studies
reported on rates of diabetic secondary complications or health-
related quality of life.
Study quality
Details of the quality of included trials are shown in Table 2.
For four[15,16,18,19] of the eight trials, randomisation was
adequate, while for the remaining four trials the randomisation
procedure was not reported or unclear. Three trials[15,16,18] had
adequate allocation concealment, while the rest of the trials did
not report on allocation concealment. All but one trial[19] were
described as double-blind. Five trials used intention-to-treat
analysis[16,18–21]. Five trials reported on follow-up
rates[15,16,18–20] and in those trials, between 77 and 92% of
participants completed the trial, without any significant differences
between comparison groups. Six of the eight trials reported that
they had carried out a power calculation[15–18,20,21]. Six trials
were reported in full and two were only available as meeting
abstracts. The two trials reported as abstracts[21,22] did not
report relevant baseline characteristics, five trials reported that
their comparison groups were similar at baseline[15,17–20], while
Berhanu 2007[16] stated that participants in the placebo group
had a slightly higher BMI at baseline and longer diabetes duration,
but it was unclear whether these differences were significant. All
but one trial[22] reported on sources of funding and all funding
included industry funding.
Data synthesis
Results of the individual trials are shown in Table 3.
HbA1c. All studies reported HbA1c values and could be
included in the meta-analysis (Figure 2). Baseline HbA1c values
were between 7.6 and 10% in the pioglitazone plus insulin groups
and between 7.8 and 9.8% in the insulin without pioglitazone
groups. End-of-study HbA1c values were significantly lower in the
groups taking pioglitazone plus insulin than in the groups taking
insulin without pioglitazone (weighted mean difference 20.58%,
95% CI: 20.70, 20.46, p,0.00001). There was no significant
heterogeneity. In the study by Mattoo 2005, 18% of patients on
pioglitazone plus insulin and 6.9% of patients on insulin without
pioglitazone attained HbA1c values of below 7.0%. There was no
significant difference between patients using two or fewer daily
injections and patients using three or more daily injections.
Similarly, there was no significant difference between patients who
had previously been on oral antidiabetic agents and those who had
Figure 1. Flow chart of search results.
doi:10.1371/journal.pone.0006112.g001
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Study and
Country Focus Interventions Characteristics of Participants
Study
Duration Outcomes measured
Asnani 2006
USA[15]
effect of pioglitazone on
vascular reactivity in
patients with insulin-
treated type 2 diabetes
1) PIO + ins: pioglitazone 30 mg at
breakfast, insulin continued as before
2) P + ins: placebo, insulin continued
as before
co-interventions: stable lipid-
lowering (statins) and antihypertensive
therapy
number: 20 (10/10)
mean age: 59/57 yrs
gender: NR
BMI: NR
ethnicity: NR
diabetes duration: 17/11 years
previous medication: NR
4 months primary: flow-mediated
dilatation
other: HbA1c, brachial
artery reactivity, laboratory
assessments, lipid profile
Berhanu 2007
USA[16]
safety and efficacy of
pioglitazone alone or in
combination with
metformin in reducing
insulin dosage
requirements for
improved glycaemic
control in patients with
type 2 diabetes
1) PIO + ins: pioglitazone titrated to
45 mg/day during first 4 weeks of
treatment, plus insulin as below
2) P + ins: identical placebo plus
insulin as below
both: daily injections of Humalog,
Humulin 70/30 or Humulin N
co-interventions: maintained stable
metformin and, as applicable,
previous statin use
number: 222 (110/112)
mean age: 52.9/52.5 yrs
gender (% female): 56.4/58.9
BMI: 30.7/31.8 kg/m
2
Ethnicity(%): Hispanic 50.0/58.9,
non-Hispanic white 34.9/25.9,
non-Hispanic black 12.7/11.6,
other 2.7/3.6
diabetes duration: 7.7/8.5 yrs
previous medication (%): SU+
MET: 90.0/92.9, insulin and MET:
8.2/5.4, insulin only:1.8/1.8
20 weeks primary: change in insulin
dosage from baseline to
study end
other: HbA1c,
hypoglycaemia, total daily
dose, weight change,
adverse event, lipid
parameters, C-peptide
Fernandez 2008
USA[17]
relationship between
glycaemic control,
vascular reactivity and
inflammation in type 2
diabetes
1) PIO + ins: pioglitazone 45 mg/day;
started at 15 mg daily, 30 mg daily in
week 2, 45 mg daily in week 4
2) P + ins: placebo (the ramipril + ins
arm not considered here)
both: patients selected between
basal-bolus therapy (bedtime insulin
glargine plus premeal insulin aspart)
or continuous subcutaneous infusion
co-interventions: nearly half the
patients were using a statin; one third
on anti-hypertensive therapy
total number: 30 (10/10) (10 in
ramipril + ins arm)
mean age: overall 46 yrs
gender: overall ,60% female
BMI: overall ,31–33 kg/m
2
ethnicity: Mexican-American
diabetes duration: overall 6.2
to 8.4 yrs
previous medication: use of
oral antidiabetic medications
similar between groups
36 weeks primary: vascular analyses
other: HbA1c,
hypoglycaemia: total daily
dose, weight change,
adverse events, vascular
studies, lipid parameters
Mattoo 2005
Worldwide [18]
effect of pioglitazone
plus insulin versus
placebo plus insulin on
glycaemic control, serum
lipid profile, and selected
cardiovascular risk
factors in patients with
type 2 diabetes
inadequately controlled
with insulin therapy
alone
1) PIO + ins: 30 mg pioglitazone plus
insulin
2) P + ins: identical placebo plus
insulin
both: insulin dose adjusted on basis
of self- monitored blood glucose levels
co-interventions: patients allowed
other medication except another oral
antidiabetic agent, systemic
glucocorticoid therapy, or nicotinic
acid (.500 mg/d).
total number: 289 (142/147)
mean age: 58.8/58.9 yrs
gender (% female): 56.3/57.1
BMI: 32.5/31.8 kg/m
2
ethnicity: % White: 96.5/96.6
diabetes duration: 163.4/160.9
months
previous medication: 149
patients previously on oral agents
(MET n=109, SU n=19, MET +
SU n=17, other n=4)
6 months primary: HbA1c change
other: hypoglycaemia, total
daily dose, weight change,
adverse events, lipid
parameters
Raz 2005
Worldwide
[19] Rosenstock
2002
(pioglitazone
014 study
group)
USA[20]
efficacy and safety of
biphasic insulin aspart
30/70 (BIAsp 30) plus
pioglitazone versus
glibenclamide plus
pioglitazone and BIAsp
30 monotherapy in
type 2 diabetes
1) PIO + ins: 30 mg pioglitazone
once daily after breakfast plus biphasic
insulin aspart 30/70 (BIAsp 30). BIAsp
30 initiated at a dose of 0.2 U/kg/day.
2) ins mono: BIAsp 30 initiated at a
dose of 0.3 U/kg/day
(PIO + glibenclamide arm not
considered here)
both: biphasic insulin aspart 30/70
(BIAsp 30)
co-interventions: no other insulin
sensitizers; no manipulation of lipid
lowering regimens
total number: 283 (93/ 97)
mean age: 56.7/55.2 yrs
gender (% female); 47/35
BMI: 29.4/29.5 kg/m
2;
ethnicity: NR
diabetes duration: 9.2/10.0 yrs
previous medication: %o f
patients taking other oral agents
with SU; none: 14.0/13.4,
acarbose: 9.7/12.4, meglitinides:
3.2/1/0, metformin: 83.9/80.4,
thiazolidinediones: 7.5/4.1
18 weeks primary: HbA1c
other: hypoglycaemia,
glycaemic excursions, total
daily dose, weight adverse
events, lipid profiles
effect of two doses of
pioglitazone (15 or
30 mg) in combination
with a stable insulin
regimen to improve
glycaemic control in
patients whose type 2
diabetes is poorly
controlled on insulin
therapy
1) PIO15 + ins: 15 mg pioglitazone
plus usual insulin regimen
2)PIO30 + ins: 30 mg pioglitazone
plus usual insulin regimen
3) P + ins: placebo plus usual insulin
regimen
both: insulin dose could be
decreased in response to
hypoglycaemia
co-interventions: lipid-lowering
medications allowed.
total number: 566 (191/188/187)
mean age: 56.9/57.5/56.7 yrs
gender (% female): 53.9/49.5/
54.5
BMI: 33.2/34.3/33.2 kg/m
2
ethnicity (% Caucasian): 74.9/
73.4/71.1
diabetes duration: NR
previous medication: 88% insulin
monotherapy; 12% combination
with oral agents; 134 patients
receiving serum lipid reducing
agent
16 weeks primary: unclear
presumably HbA1c
other: hypoglycaemia, total
daily dose, weight change,
adverse events, serum lipid
measurements
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significant difference in HbA1c was reported for the group using
15 mg/day of pioglitazone and the group using 30 mg/day. There
was no significant difference in HbA1c results when comparing
studies in which the insulin regimen was unchanged from before
the study[15,20–22] and studies using titrated insulin regimens
according to a predefined study protocol[16–19] (HbA1c differ-
ence 20.63%, 95% CI: 20.93, 20.34, with insulin as usual,
compared to 20.52%, 95% CI: 20.68, 20.35, with insulin as per
study protocol, p=0.44).
Hypoglycaemia. Six studies reported on hypoglycaemia
outcomes and could be summarised in a meta-analysis (Figure 3).
There were marginally more patients with hypoglycaemic episodes
in the pioglitazone plus insulin groups than with insulin without
pioglitazone (relative risk 1.27, 95% CI: 0.99, 1.63, p=0.06). The
results showed significant heterogeneity (p=0.001). The study by
Raz 2005 which used biphasic insulin aspart 30 (BIAsp 30) rather
than other insulin regimens contributed most to the heterogeneity.
There is evidence to suggest that BIAsp 30 is associated with a
reduced rate of nocturnal and major episodes of hypoglycaemia
compared to other types of insulin[23]. After eliminating this study
from the analysis, there remained moderate heterogeneity
(I
2=57%, p=0.05) and there was significantly more
hypoglycaemia in the pioglitazone plus insulin groups (relative
risk 1.40, 95% CI: 1.14, 1.73, p=0.002). There were no
significant differences in intervention and control groups for
hypoglycaemia either for studies in which the insulin regimen was
unchanged from before the study[15,20–22] or for studies using
titrated insulin regimens according to a predefined study
protocol[16–19]. Details regarding hypoglycaemic episodes are
shown in Table 4. Severe hypoglycaemic events were rarely seen
in the studies.
Insulin dose. Six studies[16–21] reported insulin doses (as
units per kg per day or as units per day). Only two studies reported
standard deviations, so a meta-analysis could not be carried out
reliably. Of the six studies, four found that the insulin plus
pioglitazone groups used significantly less insulin than the insulin
without pioglitazone groups (weighted mean difference 20.19 U/
kg/day or 212.03 U/day). The remaining two studies did not
report any p-values (but doses were also lower in the pioglitazone
groups). Insulin dose ranged between 42 and 64 U/day or 0.5 to
1 U/kg/day in the pioglitazone groups and between 55 and
70 U/day or 0.7 to 1.2 U/kg/day in the groups taking no
pioglitazone.
Weight change. Six studies reported weight change[16–
20,22]. However, only one of the studies reported a measure of
variability, so a meta-analysis could not be carried out reliably. In
most studies, patients in the insulin without pioglitazone groups
gained less weight than patients in the insulin plus pioglitazone
groups (mean difference 2.91 kg, range 3.85 to 23.50 kg), but no
p-values were reported. Weight change ranged between +1.4 and
+4.4 kg in the pioglitazone plus insulin groups and between 20.04
and +4.9 kg in the insulin only groups.
Lipid parameters. Four studies reported results for serum
triglycerides [16,17,19,20].
Of the four studies, only two[16,20] found significantly reduced
triglyceride values in the pioglitazone groups (reductions of
between 0.44 and 0.70 mmol/L in the pioglitazone groups
compared to insulin only).
Four studies reported on total serum cholesterol[16,17,19,20].
None of the studies found any significant difference in total
cholesterol between the pioglitazone plus insulin and the insulin
without pioglitazone groups.
Four studies reported on HDL-cholesterol[16–18,20], all
finding significantly increased values in the pioglitazone groups.
Overall, HDL cholesterol was increased by between 0.10 and
0.18 mmol/L in the pioglitazone groups compared to insulin only.
Four studies reported on LDL-cholesterol[16–18,20], with none
finding any significant difference between the pioglitazone plus
insulin and the insulin without pioglitazone groups.
Study and
Country Focus Interventions Characteristics of Participants
Study
Duration Outcomes measured
Scheen 200619
European
countries[21]
part of
PROactive trial
(investigating
only patients
concomitantly
treated with
insulin) abstract
only
effects of pioglitazone
on the secondary
prevention of
macrovascular events
in type 2 diabees
1) PIO + ins: pioglitazone plus
previous treatment; forced titration
phase in the first two months of
treatment with stepwise increase of
pioglitazone dose from 15 mg to
30 mg and then up to 45 mg
2) P + ins: placebo plus previous
treatment both: investigators encouraged
to maintain glycaemia at ,6.5%
co-interventions: proportion of
concomitant oral therapy (%): MET
alone 47/52; SU alone 16/16; MET+
SU 10/11
total number: 1760 (864/896)
age: NR for subgroup on insulin
gender: NR for subgroup on
insulin
BMI: NR for subgroup on insulin
ethnicity: NR for subgroup on
insulin
diabetes duration: NR for
subgroup on insulin
previous medication: insulin +
MET monotherapy in 53%, SU
monotherapy in 24%, MET+SU
12%
subgroups: abstract reports
subgroup of larger trial where
about one third of patients received
concomitant insulin therapy
34.5 months
(mean)
primary: (of PROactive
trial) composite endpoint:
any of all-cause mortality,
non-fatal myocardial
infarction, acute coronary
syndrome, cardiac
intervention, stroke, major
leg amputation, bypass
surgery; or revascularisation
in leg
other: HbA1c,
hypoglycaemia, total daily
dose, adverse events
Shah 2007
USA[22] abstract
only
effects of a pioglitazone
and insulin combination
versus insulin therapy
alone on body fat
distribution
1) PIO + ins: pioglitazone (30 mg
titrated to 45 mg) and insulin
2) P + ins: placebo and insulin
co-interventions: NR
total number: 25 (12/13)
mean age: NR
gender: NR
BMI: overall 36.5 kg/m
2
ethnicity: NR
diabetes duration: NR
previous medication: NR
12 to
16 weeks
primary: body fat
distribution
other: HbA1c, weight
change, subcutaneous
adipose tissue, visceral
adipose tissue (abdominal
CT scans)
PIO + ins=pioglitazone plus insulin; P + ins=placebo plus insulin; NR=not reported; MET=metformin. SU=sulphonylurea.
doi:10.1371/journal.pone.0006112.t001
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Study Outcome Baseline End of study
Change from baseline/difference
between groups
p value (between
groups)
HbA1c
Asnani 2006 HbA1c (%) PIO + ins: 10.0
SD2.3%
P + ins: 8.7 SD2.3%
PIO + ins: 8.4 SD2.0%
P + ins: 8.6 SD1.4%
p not reported (p,0.05
for pio before and
after)
Berhanu 2007 HbA1c (%) PIO + ins: 8.4
SE0.13%
P + ins: 8.6 SE0.13%
PIO + ins: 6.81%
P + ins: 7.23%
PIO + ins: 21.6 SE0.11%
P + ins: 21.4 SE0.11%
p=NS
Fernandez 2008 HbA1c (%) PIO + ins: 9.0
SD0.7%
P + ins: 9.2 SD0.4%
PIO + ins: 6.9 SD0.3%
P + ins: 7.2 SD0.1%
Mattoo 2005 HbA1c (%) PIO + ins: 8.85
SE0.11%
P + ins: 8.79 SE0.1%
PIO + ins: 8.11
SE0.09%
P + ins: 8.66 SE0.08%
PIO + ins: 20. 69 SE0.09%
P + ins: 20.13%
difference between groups 20.55
SE0.1%
p,0.002
percentage attaining
HbA1c ,7.0%
PIO + ins: 18%
P + ins: 6.9%
HbA1c subgroups:
patients using #2o r
$3 insulin injections
no significant
difference
HbA1c subgroups:
previous use of oral
antidiabetic agents
previous use of oral agents:
PIO + ins: 20.90 SE0.14%;
P + ins: 20.11 SE0.13%
no previous use of oral agents:
PIO + ins: 20.65 SE0.11%;
P + ins: 20.2 SE0.12%
no significant
difference for
subgroups
Raz 2005 HbA1c (%) PIO + ins: 9.6
SD1.3%
ins mono: 9.5
SD1.3%
PIO + ins: 8.4
SD1.2%
ins mono: 9.0 SD1.3%
p=0.008
Rosenstock 2002 HbA1c (%) PIO15 + ins: 9.75
SE0.1%
PIO30 + ins: 9.84
SE0.1%
P + ins: 9.75 SE0.1%
PIO15 + ins: 20.99 SE0.08%
PIO30 + ins: 21.26 SE0.08%
P + ins: 20.26 SE0.08%
p,0.01 pioglitazone
versus placebo
Shah 2007 HbA1c (%) PIO + ins: 7.6%
P + ins: 7.8%
PIO + ins: 7.1%
P + ins: 7.2%
p not reported,
presumably non-
significant
Scheen 2006 HbA1c (%) PIO + ins: 8.4%
P + ins: 8.5%
PIO + ins: 7.47%
P + ins: 8.05%
PIO + ins: 20.93%
P + ins: 20.45%
p,0.0001
hypoglycaemia
Berhanu 2007 patients with
hypoglycaemic events
PIO + ins: 46% (91%
mild)
P + ins: 31% (66% mild)
p,0.005
severe hypoglycaemia
(episodes)
PIO + ins: n=0
P + ins: n=4
p not reported
Fernandez 2008 patients with
hypoglycaemic episodes
PIO + ins: n=4
P + ins: n=6
Mattoo 2005 patients with subjective
hypoglycaemic episodes
PIO + ins: 63.4%
P + ins: 51.0%
p,0.05
clinical hypoglycaemic
episodes (blood glucose
,2.8 mmol/L)
no significant
difference
Raz 2005 major hypoglycaemic
episodes
none
minor hypoglycaemic
episodes (% patients)
PIO + ins: 12%
ins mono: 15%
p not reported
minor hypoglycaemic
episodes (episodes)
PIO + ins: 15
ins mono: 47
p not reported
symptoms only (%
patients)
PIO + ins: 34%
ins mono: 40%
p not reported
Pioglitazone/Insulin in DM 2
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Change from baseline/difference
between groups
p value (between
groups)
symptoms only
(episodes)
PIO + ins: 115
ins mono: 171
p not reported
incidence (per patient-
week for all episodes)
PIO + ins: 0.083
ins mono: 0.132
p,0.05
nocturnal
hypoglycaemia
(episodes)
PIO + ins: 0
ins mono: 8
p not reported
Rosenstock 2002 hypoglycaemia PIO15 + ins: 8%
PIO30 + ins: 15%
P + ins: 5% (all
considered mild to
moderate)
Scheen 2006 hypoglycaemia (not
specified further)
PIO + ins: 41%
P + ins: 29%
p,0.0001
glycaemic excursions
Raz 2005 measurements before
dinner, 90 mins after
dinner, and at bedtime
significantly lower in
PIO + ins group than in
ins monotherapy
group
total daily dose
Berhanu 2007 daily insulin dose PIO + ins: 55.8
SE2.95 units
P + ins: 57.7
SE2.95 units
PIO + ins: 212.0 SE1.84 units
P + ins: +0.8 SE1.84 units adjusted mean
difference between groups 212.7
units (95% CI: 217.5, 28.0)
p,0.001
Fernandez 2008 daily insulin dose all groups:
,1.2 U/kg/day
PIO + ins: 1.0
U/kg/day
P + ins: ,1.2
U/kg/day
p not reported
Mattoo 2005 daily insulin dose PIO + ins: 0.96
SE0.03 U/kg/day
P + ins: 0.92
SE0.03 U/kg/day
PIO + ins: 0.76
SE0.02 U/kg/day
P + ins: 0.94
SE0.02 U/kg/day
difference between groups 20.18
SE0.02 U/kg/day
p,0.002
Raz 2005 daily insulin dose PIO + ins: 0.2
U/kg/day
ins mono: 0.3
U/kg/day
PIO + ins: 0.5
U/kg/day
ins mono: 0.7
U/kg/day
PIO + ins: +0.3 U/kg/day
ins mono: +0.4 U/kg/day
p=0.002
Rosenstock 2002 daily insulin dose PIO15 + ins: 70.2
SE34.0 U/day
PIO30 + ins: 72.3
SE38.5 U/day
P + ins: 70.7
SE33.5 U/day
PIO15 + ins: 67.3
SE33.5 U/day
PIO30 + ins: 64.2
SE32.7 U/day
P + ins: 70.1
SE33.9 U/day
p not reported
Scheen 2006 daily insulin dose PIO + ins: 47
U/day
P + ins: 47 U/day
PIO + ins: 42 U/day
P + ins: 55 U/day
p,0.0001; at final visit,
insulin discontinued in
9% of pioglitazone
group and 2% of
placebo group
(p,0.0001)
weight change
Berhanu 2007 weight (kg) PIO + ins: +4.39 kg
P + ins: +2.42 kg
p not reported
patients reporting
weight gain
PIO + ins: n=10
P + ins: n=3
p not reported
Fernandez 2008 weight (kg) PIO + ins: +4.4 kg
P + ins: +1.7 kg
p not reported
Mattoo 2005 weight (kg) PIO + ins: +4.05 SE4.03 kg
P + ins: +0.20 SE2.92 kg
p not reported
Raz 2005 weight (kg) PIO + ins: +4.0 kg
ins mono: +2.2 kg
p not reported
Table 3. Cont.
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Change from baseline/difference
between groups
p value (between
groups)
patients experiencing
weight gain (%)
PIO + ins: 8%
ins mono: 2%
p not reported
Rosenstock 2002 weight (kg) PIO15 + ins: 95.4
SE17.6 kg
PIO30 + ins: 98.7
SE17.7 kg
P + ins: 95.4
SE17.0 kg
PIO15 + ins: +2.3 kg
PIO30 + ins: +3.7 kg
P + ins: 20.04 kg
p not reported; weight
gain related to
decreases in HbA1c,
p=0.002
Shah 2007 weight (kg) PIO + ins:
107.1 kg
P + ins: 108.7 kg
PIO + ins: 112.0 kg
P + ins: 110.1 kg
p not reported,
presumably non-
significant
lipid parameters
Berhanu 2007 total cholesterol
(mg/dL)
PIO + ins: 178
SE3.53 mg/dL
P + ins: 183
SE3.6 mg/dL
PIO + ins: +5.7 SE2.75 mg/dL
P + ins: +4.7 SE2.78 mg/dL
p=NS
HDL cholesterol
(mg/dL)
PIO + ins: 44.6
SE1.3 mg/dL
P + ins: 42
SD1.3 mg/dL
PIO + ins: +4.3 SE0.75 mg/dL
P + ins: 20.2 SE0.77 mg/dL
p,0.001
LDL cholesterol
(mg/dL)
PIO + ins: 107
SE3.1 mg/dL
P + ins: 111
SE3.2 mg/dL
PIO + ins: +4.0 SE2.37 mg/dL
P + ins: +0.9 SE2.37 mg/dL
p=NS
triglycerides (mg/dL) PIO + ins: 123
SE7.5 mg/dL
P + ins: 141
SE7.6 mg/dL
PIO + ins: 20.2 SE9.80 mg/dL
P + ins: +43.7 SE9.96 mg/dL
p,0.001
Fernandez 2008 total cholesterol
(mg/dL)
PIO + ins: 176
SD9 mg/dL
P + ins: 195
SD9 mg/dL
PIO + ins: 175
SD16 mg/dL
P + ins: 180
SD8 mg/dL
p=NS
LDL cholesterol
(mg/dL)
PIO + ins: 107
SD7 mg/dL
P + ins: 121
SD8 mg/dL
PIO + ins: 105
SD12 mg/dL
P + ins: 115
SD7 mg/dL
p=NS
HDL cholesterol
(mg/dL)
PIO + ins: 45
SD3 mg/dL
P + ins: 49
SD4 mg/dL
PIO + ins: 51
SD3 mg/dL
P + ins: 46
SD3 mg/dL
p,0.05 pioglitazone
versus baseline
VLDL cholesterol
(mg/dL)
PIO + ins: 109
SD16 mg/dL
P + ins: 113
SD24 mg/dL
PIO + ins: 88
SD15 mg/dL
P + ins: 93
SD19 mg/dL
triglycerides (mg/dL) PIO + ins: 148
SD17 mg/dL
P + ins: 146
SD15 mg/dL
PIO + ins: 123
SD11 mg/dL
P + ins: 132
SD18 mg/dL
Mattoo 2005 HDL cholesterol
(mmol/L)
PIO + ins: 1.23
SE0.03 mmol/L
P + ins: 1.24
SE0.03 mmol/L
PIO + ins: 1.35
SE0.02 mmol/L
P + ins: 1.21
SE0.02 mmol/L
difference between groups 0.13
SE0.03 mmol/L
p,0.002
LDL cholesterol
(mmol/L)
PIO + ins: 3.20
SE0.09 mmol/L
P + ins: 3.18
SE0.08 mmol/L
PIO + ins: 3.18
SE0.06 mmol/L
P + ins: 3.10
SE0.06 mmol/L
p=NS
Raz 2005 triglycerides (mg/dL) PIO + ins: 149
SD88 mg/dL
ins mono: 158
SD88 mg/dL
p=NS
total cholesterol
(mg/dL)
PIO + ins: 212 mg/dL
ins mono: 204 mg/dL
p=NS
HDL cholesterol
(mg/L)
difference between PIO + ins versus
ins mono +4 SD1 mg/dL
p,0.01
Table 3. Cont.
Pioglitazone/Insulin in DM 2
PLoS ONE | www.plosone.org 10 July 2009 | Volume 4 | Issue 7 | e6112Study Outcome Baseline End of study
Change from baseline/difference
between groups
p value (between
groups)
LDL cholesterol
(mg/L)
no data shown p=NS
Rosenstock 2002 triglycerides (mmol/L) PIO15 + ins: 2.61
SE0.2 mmol/L
PIO30 + ins: 2.96
SE0.2 mmol/L
P + ins: 2.74
SE0.2 mmol/L
LS % mean change from baseline
PIO15 + ins: +5.35 SE6.56%
PIO30 + ins: 210.35 SE6.54%
P + ins: +13.30 SE6.63%
p,0.05 PIO30 versus
placebo
HDL cholesterol
(mg/dL)
PIO15 + ins: 43.42
SE0.95 mg/dL
PIO30 + ins: 42.71
SE0.94 mg/dL
P + ins: 42.66
SE0.96 mg/dL
LS % mean change from baseline
PIO15 + ins: +7.07 SE1.58%
PIO30 + ins: +9.13 SE1.57%
P + ins: 20.21 SE1.59%
p,0.05 PIO30 versus
placebo
total cholesterol
(mg/dL)
PIO15 + ins: 213.08
SE3.57 mg/dL
PIO30 + ins: 207.32
SE3.53 mg/dL
P + ins: 214.03
SE3.58 mg/dL
LS % mean change from baseline
PIO15 + ins: +1.40 SE1.06%
PIO30 + ins: +0.40 SE1.05%
P + ins: 20.66 SE1.07%
p=NS
LDL cholesterol
(mg/dL)
PIO15 + ins: 127.33
SE3.07 mg/dL
PIO30 + ins: 121.69
SE3.06 mg/dL
P + ins: 130.95
SE3.05 mg/dL
LS % mean change from baseline
PIO15 + ins: +2.83 SE1.80%
PIO30 + ins: +5.05 SE1.71%
P + ins: 21.41 SE1.74%
p=NS
adverse events
Berhanu 2007 oedema PIO + ins: n=10
P + ins: n=5(all mild to moderate)
p not reported
serious adverse events PIO + ins: n=4
P + ins: n=2(none considered to be
related to study medication)
p not reported
Fernandez 2008 mild peripheral
oedema
PIO + ins: n=3
P + ins: n=0
p not reported
Mattoo 2005 withdrawal due to
adverse events
PIO + ins: n=7
P + ins: n=3
p not reported
oedema PIO + ins: n=20 (10 classified as mild)
P + ins: n=5 (3 classified as mild)
p not reported
Raz 2005 withdrawal due to
adverse events
PIO + ins: n=1
ins mono: n=2
p not reported
patients with product-
related adverse events
PIO + ins: 28%
ins mono: 20%
p not reported
peripheral oedema PIO + ins:6 %
ins mono: 0
p not reported
serious adverse events PIO + ins: n=0
ins mono: n=2 (none considered to be
related to study medication)
Rosenstock 2002 withdrawal due to
adverse events
PIO15 + ins: 1.6%
PIO30 + ins: 2.6%
P + ins: 3.2%
p not reported
oedema PIO15 + ins: 12.6%
PIO30 + ins: 17.6%
P + ins: 7.0%
p not reported
Scheen 2006 oedema PIO + ins: 31%
P + ins: 18%
p,0.0001
cardiac adverse events
Berhanu 2006 insulin only patients had a higher incidence
of cardiac events (10.7% versus 5.5%), the
majority of which were ECG abnormalities;
one patient each with myocardial infarction
and cardiac hypertrophy in the insulin only
group; one patient with coronary artery
disease in the pioglitazone group; no deaths
Table 3. Cont.
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any significant difference in withdrawals due to adverse events
between the pioglitazone plus insulin and the insulin without
pioglitazone groups. Apart from weight gain and hypoglycaemia,
the only adverse event reported as occurring more frequently with
pioglitazone was (peripheral) oedema, which was generally
classified as mild to moderate. However, p-values were generally
not reported.
Only three trials reported on cardiovascular adverse
events[16,19,20] (and most studies were probably underpowered
for coming to reliable conclusions). In the trial by Berhanu 2006,
insulin only patients had a higher incidence of cardiac events
(10.7% versus 5.5%) but the majority were ECG abnormalities
rather than patient oriented outcomes; there was one patient each
with myocardial infarction and cardiac hypertrophy in the insulin
only group, and one patient with coronary artery disease in the
Study Outcome Baseline End of study
Change from baseline/difference
between groups
p value (between
groups)
Raz 2005 2 cases of myocardial infarction in insulin
monotherapy group (not considered to be
treatment-related)
Rosenstock 2002 rate of cardiovascular adverse events 7.9%
pioglitazone, 7.0% insulin only, no significant
difference; congestive heart failure in 2
patients receiving 15 mg/day pioglitazone and
in 2 patients receiving 30 mg/day
pioglitazone, all in patients with history of
cardiovascular disease and none considered to
be drug-related
HR QoL not reported
HR QoL=health-related quality of life; SD=standard deviation; SE=standard error
doi:10.1371/journal.pone.0006112.t003
Table 3. Cont.
Figure 2. Forest plot of HbA1c results; SD=standard deviation, IV=inverse variance method, pio=pioglitazone, ins=insulin.
doi:10.1371/journal.pone.0006112.g002
Figure 3. Forest plot of frequency of hypoglycaemia; M-H=Mantel-Haenszel, pio=pioglitazone, ins=insulin.
doi:10.1371/journal.pone.0006112.g003
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two cases of myocardial infarction in the insulin monotherapy
group which were not considered to be treatment-related.
Rosenstock 2002 observed a rate of cardiovascular adverse events
of 7.9% with pioglitazone plus insulin and of 7.0% with insulin
only (no significant difference); congestive heart failure was seen in
two patients receiving 15 mg/day pioglitazone and in two patients
receiving 30 mg/day pioglitazone. All cases were in patients with a
history of cardiovascular disease and none were considered to be
drug-related.
Heterogeneity. We performed a range of subgroup analyses,
these included: insulin therapy ‘‘as usual’’ versus insulin
individually titrated for the study, pioglitazone increased/titrated
up to 45 mg versus constant dose of 30 mg, abstract only versus
full publication, baseline HbA1c ,8.5 or 9% versus $8.5 or 9%,
comparison group n,100 versus n.100, study duration ,6
months versus $6 months, study quality 5 or 6 or more criteria
fulfilled versus less than 5 or 6 criteria fulfilled. No significant
differences in study results were seen for any of the subgroup
analyses.
Discussion
Summary
Eight randomised controlled trials were identified comparing
combinations of insulin and pioglitazone with insulin without
pioglitazone regimens (two published as abstracts only). Compared
to the insulin regimens, the pioglitazone plus insulin regimens
reduced HbA1c by a mean of 20.58% (95% CI: 20.70, 20.46,
p,0.00001). However, hypoglycaemic events were marginally
increased with the pioglitazone regimens (relative risk 1.27, 95%
CI: 0.99, 1.63, p=0.06). Where reported, studies found reduced
insulin doses in the pioglitazone groups. HDL-cholesterol was
increased, but none of the other lipid parameters reported
(triglycerides, total cholesterol, LDL-cholesterol) showed any
systematic differences between the comparison groups. The studies
tended to show increased weight (mean difference 2.91 kg) and
more peripheral oedema with pioglitazone. No conclusions could
be made regarding cardiovascular events.
This review adds to the current body of evidence in two ways.
First, by demonstrating some added value of pioglitazone when
added to insulin-containing regimens, and secondly by making the
point that starting patients on insulin does not mean that all
further intensifications need to occur by adding more insulin.
Limitations
The main evidence gap relates to long-term safety. The studies
included in this review were too short-term and too few in number
to assess longer-term adverse effects. Recent debates on the TZDs
have focused on cardiovascular events, following the review by
Nissen and colleagues[24], which concluded that the risk of
cardiovascular events was increased by rosiglitazone. A meta-
analysis by Monami et al. (2008)[25] aimed to identify moderators
of the effect of rosiglitazone on incidence of myocardial infarction
and found that there was a significant correlation between the
proportion of insulin-treated patients and rosiglitazone-associated
risk of myocardial infarction (r=0.42, p,0.05) (possibly related to
the fact that both thiazolidinediones and insulin have an effect on
fluid retention). Similar data are not available for pioglitazone.
A meta-analysis of the risk of cardiovascular events with
pioglitazone was carried out by Lincoff et al. (2007)[26]. Based
on 19 trials with 16,930 participants, they concluded that
pioglitazone was associated with a reduced risk of death,
myocardial infarction or stroke.
Table 4. Details of hypoglycaemic episodes.
Study Definition of hypoglycaemia Classification of hypoglycaemic episodes
Asnani 2006 hypoglycaemia not reported hypoglycaemia not reported
Berhanu 2006 self-monitored blood glucose ,3.3 mmol/L or laboratory value
,3.9 mmol/L, more than two simultaneous hypoglycaemia symptoms
relieved by oral glucose-containing substance, or resulting in needing
assistance for simple tasks
more hypoglycaemic events in the pioglitazone group, but almost
all (91%) rated as mild compared to 66% in the insulin only group; 0
severe hypoglycaemic events versus 4 in the insulin only group
Fernandez 2008 symptomatic hypoglycaemia requiring glucose ingestion 6 patients in insulin only group and 4 patients in pioglitazone plus
insulin group with hypoglycaemic episodes as defined; 33
hypoglycaemic episodes (0.32 patients per year)
Mattoo 2005 1) subjective symptoms only, 2) subjective symptoms with a
self-monitored blood glucose level $2.8 mmol/L, 3) subjective symptoms
with a self-monitored blood glucose level ,2.8 mmol/L, and 4)
self-monitored blood glucose ,2.8 mmol/L without symptoms; severe:
patient either had blood glucose ,2.8 mmol/L or promptly recovered
after oral carbohydrate, glucagon, or intravenous glucose, but required
the assistance of another person for recovery, non-severe: patient did not
require assistance of another person for recovery, regardless of blood
glucose level
no difference between groups in rate of hypoglycaemic incidents or
number of clinical hypoglycaemic episodes (blood glucose
,2.8 mmol/L); 63.4% of patients with subjective hypoglycaemic
episodes in pioglitazone plus insulin group versus 51.0% for insulin
only (p,0.05) but no difference for other types of hypoglycaemia
Raz 2005 major: unable to self-treat, blood glucose ,2.8 mmol/L, or symptoms
remitted after administration of intravenous glucose or intramuscular
glucagon or after food intake; minor: blood glucose ,2.8 mmol/L and
patient handled the event without assistance from others; symptomatic:
hypoglycaemic symptoms present but not confirmed with blood glucose
measurement, assistance from others not required
no major hypoglycaemic episodes; 56% of patients in insulin only
group had hypoglycaemic episodes (72% symptoms only, 28%
minor), 8 events of nocturnal hypoglycaemia; 46% of patients in the
pioglitazone group had hypoglycaemic events (74% symptomatic,
26% minor), no nocturnal hypoglycaemia; p-value not reported
Rosenstock 2002 fasting plasma glucose #5.6 mmol/L on two occasions or symptoms of
hypoglycaemia not explained by other conditions
all considered mild or moderate; most self-treated with caloric
intake; all reported while patients were at home
Scheen 2006 not reported not reported
Shah 2007 hypoglycaemia not reported hypoglycaemia not reported
doi:10.1371/journal.pone.0006112.t004
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ed 84 published and 10 unpublished trials of pioglitazone
compared to placebo or active comparators, but excluded the
PROactive trial. They reported a reduction of all-cause mortality
with pioglitazone (OR 0.30; 95% CI: 0.14 to 0.63: p,0.05), but
no significant effect on non-fatal coronary events.
Several new studies have asked why rosiglitazone should
increase cardiovascular events but pioglitazone does not. Most
have concluded that the likely reason is that while the two
glitazones have the same effects on glycaemic control, and the
same side-effects of fluid retention and heart failure, they have
different effects on blood lipids. Berneis and colleagues[28] carried
out a very small cross-over trial in 9 patients, giving them all 12
weeks on pioglitazone and 12 weeks on rosiglitazone. Total
cholesterol increased more on rosiglitazone than on pioglitazone
(p=0.04), and triglycerides increased on rosiglitazone but
decreased on pioglitazone (p=0.004).
Chappuis and colleagues[29] also studied patients on both
glitazones, this time with 17 patients having 12 weeks on each.
The effects of HbA1c were similar, but triglyceride and cholesterol
levels were lower with pioglitazone.
Deeg and colleagues[30] carried out a much larger comparison
with 369 participants randomised to pioglitazone and 366 to
rosiglitazone. After 12 weeks, pioglitazone had reduced LDL
whereas rosiglitazone had increased it.
The other concern about the safety of the glitazones has been
the fracture risk. Kahn and colleagues[31] in the ‘‘durability’’
study (ADOPT) reported that 9.3% of women on rosiglitazone
had fractures compared to 5.1% on metformin and 3.5% on
glibenclamide. The increases were in fractures of upper limb and
foot, rather than in the classical osteoporosis-associated neck of
femur and vertebrae. The fracture rates in men did not differ
between treatment groups.
A case-control study by Meier and colleagues[32] using British
general practice data from GPRD also found that use of glitazones
was associated with increased fracture rates. No such increase was
seen with other oral diabetes drugs.
A recent (non-systematic) review by Schwartz (2008)[33]
summarised clinical data on bone loss associated with use of
glitazones. This reiterates data from recent trials reporting
increased fracture risk in women (but not men) and reports
evidence from short term clinical trials in women that glitazones
(both pioglitazone and rosiglitazone) caused more rapid bone loss.
It also reports data from in vitro and rodent models suggesting that
activation of the PPAR-gamma receptor can play a role in bone
loss.
A letter to physicians issued by Takeda Pharmaceuticals (posted
on the US Food and Drug Administration website in March 2007)
reported an analysis of its clinical trials database on pioglita-
zone[34]. They compared the incidence of fractures in over 8100
patients treated with pioglitazone compared to over 7400 patients
treated with a comparator. The fracture incidence calculated was
1.9 fractures per 100 patient years in women treated with
pioglitazone and 1.1 fractures per 100 patient years in women
treated with a comparator. The observed excess risk of fractures
for women in this dataset on pioglitazone is therefore 0.8 fractures
per 100 patient years of use. There was no increased risk of
fractures identified in men.
The more drugs a patient has to take, the poorer the adherence.
Donnan and colleagues from Dundee[35] found that even those
on only one glucose lowering agent have poor adherence, with
adequate adherence in only one in three. Adherence is better with
a single daily dose[35]. Those taking other medications had poorer
compliance than those on just a hypoglycaemic agent.
A systematic review of medication adherence in patients with
poorly controlled diabetes by Odegard and colleagues[36]
summarises the barriers to taking medicines, and the interventions
which may help. Some of the studies are more relevant to the
North American situation where people have to pay for drugs, but
much of it is relevant to the UK. The review concurs with the
work of Donnan and colleagues (mentioned above), that common
barriers to adherence include complexity of regimen and number
of doses.
The implication for the treatment of type 2 diabetes may be that
both the number of drugs and the number of tablets or injections
per day should be kept as low as possible[37].
Conclusions
When added to insulin regimens, pioglitazone confers a small
but clinically useful decrease in HbA1c of 0.58% in type 2 diabetes
patients with previous inadequate glucose control. However it does
so at the cost of increased hypoglycaemia and weight gain, with a
risk of heart failure, and of fractures in women. The effect on
adherence of adding another medication needs to be considered,
as does the extra cost, though that is offset by the reduced insulin
dose required.
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